Evidenced-based pharmacologic treatment of borderline personality disorder: A shift from SSRIs to anticonvulsants and atypical antipsychotics?

2008 ◽  
Vol 111 (1) ◽  
pp. 21-30 ◽  
Author(s):  
P. Francis Abraham ◽  
Joseph R. Calabrese

Until recently, borderline personality disorder (BPD) has been the stepchild of psychiatric disorders. Many researchers even questioned its existence. Clinicians have been reluctant to reveal the diagnosis to patients because of the stigma attached to it. But individuals with BPD suffer terribly and a significant proportion die by suicide and engage in nonsuicidal self-injury. The aim of this primer on BPD is to fill this void and provide clinicians with an accessible, easy-to-use, clinically oriented, evidenced-based guide for early-stage BPD. We present the most up to date data about BPD by leading experts in the field in a format accessible to trainees and professionals working with individuals with BPD and their family members. The volume is comprehensive and covers the etiology of BPD, its clinical presentation and comorbid disorders, genetics and neurobiology of BPD, effective treatment approaches to BPD, the role of advocacy, and the treatment of special subpopulations (e.g., forensic) in the clinical management of BPD.


2010 ◽  
Vol 32 (3) ◽  
pp. 189-205 ◽  
Author(s):  
Gregory Hatchett

Many psychiatrists have reconceptualized borderline personality disorder (BPD) as a variant of bipolar disorder and, consistent with the treatment of bipolar disorder, emphasize the use of mood stabilizers and atypical antipsychotics in treatment. This change in diagnostic practice is unfortunate. BPD is a distinct diagnostic construct, and clients who fit this pattern require a fundamentally different treatment approach than what is typically recommended for bipolar disorder. The purpose of this article is to update counselors on the expansion of bipolar disorder in the psychiatric literature, present evidence for the validity of BPD, discuss strategies for the differential diagnosis of it from bipolar disorder, review proposed changes in DSM-V, and integrate the literature into a mental health counseling framework.


2016 ◽  
Vol 15 (5) ◽  
pp. 392-408
Author(s):  
James P. Loveless ◽  
Matthew C. Whited ◽  
Ashley C. Rhodes ◽  
Tony Cellucci

Author(s):  
Kenneth R. Silk ◽  
Louis Feurino

The purpose of this chapter is to review the literature concerning the psychopharmacology of personality disorders. We first review the double-blind placebo-controlled pharmacologic studies of all the personality disorders, except for borderline personality disorder (BPD). Attention is then focused on BPD. While there have been many open-labeled studies, there are fewer than 30 randomized-controlled trials even for this personality disorder. The section on borderline personality disorder will conclude with guidance as to how to think about the management of the actual pharmacologic treatment of this disorder, including matters such as dosage, lethality, augmentation, and avoiding polypharmacy. We conclude with a discussion of the obstacles hampering the development of a more substantial database that could provide guidance and direction.


2014 ◽  
Vol 32 (4) ◽  
pp. 318-324 ◽  
Author(s):  
Elizabeth B Stuyt

Objectives Retention of individuals with co-occurring borderline personality disorder (BPD) and substance use disorders in treatment is known to be difficult. An outcome study of a tobacco-free 90-day inpatient dual-diagnosis treatment programme that uses several evidenced-based treatments in addition to ear acupuncture (acudetox) was undertaken to determine overall treatment effectiveness. Methods Between January 2009 and December 2011, 231 patients were treated in the programme, 88% with nicotine dependence and 79% with personality disorder diagnoses. All patients completing the programme were invited to enrol in a 1-year follow-up study in which they responded to monthly questionnaires to assess outcomes. Results 185 patients (80%) successfully completed the programme. There was no correlation between successful programme completion and gender, race, age, primary drug dependence diagnosis or primary psychiatric diagnosis. The use of acudetox was positively correlated with successful completion (p=0.006). Of the 78 patients with BPD, 100% of men and 83% of women successfully completed the programme. Their use of acudetox was positively correlated with successful completion (p=0.026). At the end of the year, 140 questionnaires were returned: 51 patients with BPD reported outcomes similar to the group as a whole, with 55% sober and doing well. Conclusions The use of acudetox was positively correlated with both successful completion of the programme for those with BPD as well as successful tobacco cessation, which ultimately improves the ability to maintain sobriety.


Author(s):  
Heidi L. Heard ◽  
Marsha M. Linehan

This chapter elaborates on the multiple integrative aspects of dialectical behavior therapy (DBT), an evidenced-based treatment for individuals who meet criteria for borderline personality disorder (BPD). It discusses how behavioral theory, Zen, and dialectics provide the primary principles and describes how the dialectical principles perform various integrating roles throughout the therapy. It also clarifies the construct of traumatic invalidation, a component of the treatment’s biosocial theory. The section on methods describes key therapeutic strategies, including problem-solving and validation. A case example illustrates the dialectical and integrative nature of the treatment. The chapter also reviews the results of randomized controlled trials examining the efficacy of DBT for BPD and identifies the settings, ages, and other clinical disorders for which the treatment also has empirical support.


2006 ◽  
Vol 39 (3) ◽  
pp. 117-118 ◽  
Author(s):  
J. Pascual ◽  
M. Madre ◽  
J. Soler ◽  
J. Barrachina ◽  
M. Campins ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document